26272-83-3

Basic information

• Product Name: TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER
• Synonyms: TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER;3-Oxetanyl tosylate;3-(tosyloxy)oxetane;3-Oxetanyl p-toluenesulfonate, 96%;3-Ts-oxetan;oxetan-3-yl 4-Methylbenzene-1-sulfonate;3-Oxetanyl p-Toluenesulfonate
• CAS NO: 26272-83-3
• Molecular Formula: C₁₀H₁₂O₄S
• Molecular Weight: 228.26488
• Product Categories: Heterocycles
• Mol File: 26272-83-3.mol
• Article Data: 21

Chemical Properties

• Melting Point: 81.0 to 86.0 °C
• Boiling Point: 372℃
• Flash Point: 179°(354°F)
• Appearance: /
• Density: 1.34
• Vapor Pressure: 2.18E-05mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER(26272-83-3)
• EPA Substance Registry System: TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER(26272-83-3)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 26272-83-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER is used as a high-purity intermediate for the synthesis of complex molecules in the pharmaceutical industry. Its unique chemical properties and reactivity contribute to the development of innovative drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER serves as a key intermediate in the production of various agrochemicals, including pesticides and herbicides. Its high purity and reactivity enable the creation of effective and targeted agricultural products.
Used in Specialty Chemicals Industry:
TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER is utilized as an essential building block in the synthesis of specialty chemicals, which are used in a wide range of applications, such as coatings, adhesives, and sealants. Its stability and purity ensure the production of high-quality specialty chemicals.
Used as a Reagent for Organic Synthesis:
TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER is employed as a reagent in organic synthesis, facilitating various chemical reactions and transformations. Its unique properties make it a versatile and efficient reagent in the synthesis of complex organic molecules.
Used as a Stabilizer for Chlorine-Containing Compounds:
In the chemical industry, TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER is used as a stabilizer for chlorine-containing compounds. Its ability to prevent the decomposition and degradation of these compounds contributes to their stability and longevity.
Used as a Solvent for Resins and Polymers:
TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER also serves as a solvent for various resins and polymers, enabling their dissolution and application in different industries, such as coatings, adhesives, and plastics manufacturing. Its compatibility with a wide range of materials makes it a valuable solvent in the chemical industry.

InChI:InChI=1/C10H12O4S/c1-8-2-4-10(5-3-8)15(11,12)14-9-6-13-7-9/h2-5,9H,6-7H2,1H3

Upstream product

• 7748-36-9 oxetan-3-ol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 26272-85-5 3-iodooxetane 
• 1369534-96-2 3-(4-bromophenoxy)oxetane 
• 1393100-37-2 4-nitro-1-(oxetan-3-yl)-1H-pyrazole 
• 6735-33-7 3-phenoxyoxetane 
• 148430-81-3 oxetan-3-yl methane sulfonate 
• 95257-22-0 3-(benzyloxy)oxetane 

Relevant articles and documents

Synthesis of Electron-Deficient Oxetanes. 3-Azidooxetane, 3-Nitrooxetane, and 3,3-Dinitrooxetane

A facile synthesis of 3-hydroxyoxetane is described and is based on the addition of acetic acid to epichlorohydrin, protection of the resulting primary alcohol as an acetal, basic acetate hydrolysis and ring closure, and removal of the protecting group. 3-Azidooxetane was prepared from 3-(tosyloxy)oxetane and sodium azide.Reduction of the azide with triphenylphosphine or hydrogen gave 3-aminooxetane, and oxidation of the amine with m-chloroperbenzoic acid gave 3-nitrooxetane.Oxidative nitration or reaction with tetranitromethane gave 3,3-dinitrooxetane. 3-Azidooxetane and 3,3-dinitrooxetane were polymerized with Lewis acids.

A GAP Replacement: Improved Synthesis of 3-Azidooxetane and Its Homopolymer Based on Sulfonic Acid Esters of Oxetan-3-ol

In the field of energetic binders, only hydroxy-terminated glycidyl azide polymer (GAP) has found widespread application and prevailed in the market. However, oxiranes such as glycidyl azide (GA) allow two ring-opening modes during polymerization and thus

Fused tricyclic derivative as FGFR4 inhibitor

The present invention provides a fused tricyclic derivative that is the selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), a pharmaceutical composition containing the compound, a method of making the compound and a method of treating cell proliferative diseases, such as cancer, using the compounds of the invention.

AZA-QUINOLINE COMPOUNDS AND USES THEREOF

Provided aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds; and the use of such compounds for treating a disease or condition mediated by Enhancer of Zeste Homolog 2 (EZH2), Polycomb Repressive Complex 2 (PRC2), or a combination thereof.

Compounds and their use in treatment on hepatitis B

The invention provides compounds, a pharmaceutical composition containing the compounds and an application of the compounds. The compound is a compound shown in a formula (I) or a stereoisomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The compound provided by the invention can interfere with the shell assembly process of hepatitis B virus, thereby inhibiting hepatitis B virus replication. Moreover, the compound has good absorption, relatively high biological activity and availability and low toxicity, particularly has relatively strong stability in vivo, is not easy to decompose and has long drug effect time, so that an effect of treating hepatitis B is achieved and the compound has a goodapplication prospect.

8-substituted styryl xanthine derivative and application thereof

The invention discloses an 8-substituted styryl xanthine derivative and application thereof, and particularly relates to a novel 8-substituted styryl xanthine derivative and a pharmaceutical composition containing the compound, and the 8-substituted styryl xanthine derivative can be used as a selective adenosine A2A receptor antagonist. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in preparation of drugs for treating adenosine A2A receptor related diseases, especially Parkinson's disease.

Nitrogen-containing fused tricyclic derivative and application thereof

The invention discloses a nitrogen-containing fused tricyclic derivative and application thereof, and particularly relates to a novel nitrogen-containing fused tricyclic derivative and a pharmaceutical composition containing the nitrogen-containing fused tricyclic derivative, and the nitrogen-containing fused tricyclic derivative can be used as a selective adenosine A2A receptor antagonist. The invention also relates to a method for preparing the compound and the pharmaceutical composition and application of the compound and the pharmaceutical composition in preparation of drugs for treating adenosine A2A receptor related diseases, especially Parkinson's disease.

BICYCLIC AND TRICYCLIC COMPOUNDS

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

QUINAZOLINE DERIVATIVE AND USE THEREOF

The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as Pan-HER tyrosine kinase inhibitors.

2 Tyrosine kinase mediated signal transduction inhibitors

Disclosed herein are compounds of Formula (), and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, X, X, X, X, X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.